REG - Oxford Biomedica PLC - Notice of Preliminary Results

Oxford BioMedicaAnnouncement

30/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230330:nRSd6943Ua&default-theme=true

RNS Number : 6943U  Oxford Biomedica PLC  30 March 2023

 

 

Notice of Preliminary Results

 

 

 

Oxford, UK - 30 March 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"
or "the Company"), a leading gene and cell therapy group, will be announcing
its preliminary results for the twelve months ended 31 December 2022 on
Thursday, 20 April 2023.

 

Frank Mathias, Chief Executive Officer, Stuart Paynter, Chief Financial
Officer, and Kyriacos Mitrophanous, Chief Scientific Officer will host a
briefing and Q&A session for analysts at 13:00 BST / 8:00 ET on the day of
results at the London Stock Exchange, 10 Paternoster Square, London, EC4M 7LS.
 Simultaneous to the meeting, a webcast and conference call will take place
and details will be made available on the Company's website at www.oxb.com
(http://www.oxb.com) . A replay of the webcast will be made available shortly
afterwards.

 

Please contact Consilium Strategic Communications for further details.

 

 

-Ends-

 

Enquiries:

 

 

Oxford Biomedica plc:

 

Frank Mathias, Chief Executive Officer - T: +44 (0)1865 783 000

Stuart Paynter, Chief Financial Officer - T: +44 (0)1865 783 000

Taylor Boyd, VP, Head of IR - T: +1 (984) 268 8488 / E: ir@oxb.com

Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 7394 562 425 / E:
ir@oxb.com

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Cole            / Matthew Neal

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform, and
is working on programmes from pre-clinical to commercial stage across a range
of therapeutic areas with global partners.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a
US based subsidiary AAV manufacturing and innovation business, based near
Boston, US.

 

Further information is available at www.oxb.com (http://www.oxb.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOREAEDNAFXDEAA